174 related articles for article (PubMed ID: 21575885)
1. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease.
Levine A; Turner D
J Crohns Colitis; 2011 Jun; 5(3):222-6. PubMed ID: 21575885
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
Levine A; Kori M; Kierkus J; Sigall Boneh R; Sladek M; Escher JC; Wine E; Yerushalmi B; Amil Dias J; Shaoul R; Veereman Wauters G; Boaz M; Abitbol G; Bousvaros A; Turner D
Gut; 2019 Feb; 68(2):239-247. PubMed ID: 29420227
[TBL] [Abstract][Full Text] [Related]
3. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort.
Sprockett D; Fischer N; Boneh RS; Turner D; Kierkus J; Sladek M; Escher JC; Wine E; Yerushalmi B; Dias JA; Shaoul R; Kori M; Snapper SB; Holmes S; Bousvaros A; Levine A; Relman DA
Inflamm Bowel Dis; 2019 Nov; 25(12):1927-1938. PubMed ID: 31276165
[TBL] [Abstract][Full Text] [Related]
5. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
6. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
8. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.
Prantera C; Berto E; Scribano ML; Falasco G
Ital J Gastroenterol Hepatol; 1998 Dec; 30(6):602-6. PubMed ID: 10076781
[TBL] [Abstract][Full Text] [Related]
9. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
Reinisch W; Wang Y; Oddens BJ; Link R
Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
[TBL] [Abstract][Full Text] [Related]
12. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
13. Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease.
Landorf E; Hammond P; Abu-Assi R; Ellison S; Boyle T; Comerford A; Couper R
J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1279-1286. PubMed ID: 38623960
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
15. The role of antimicrobials in Crohn's disease.
Kale-Pradhan PB; Zhao JJ; Palmer JR; Wilhelm SM
Expert Rev Gastroenterol Hepatol; 2013 Mar; 7(3):281-8. PubMed ID: 23445237
[TBL] [Abstract][Full Text] [Related]
16. Combination ciprofloxacin and metronidazole for active Crohn's disease.
Greenbloom SL; Steinhart AH; Greenberg GR
Can J Gastroenterol; 1998; 12(1):53-6. PubMed ID: 9544412
[TBL] [Abstract][Full Text] [Related]
17. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
18. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
19. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
